1. The status of TKI/acid-suppressant concomitant use in 44 hospitals in China: A cross-sectional descriptive study
   Fangting Chen et al, 2022, Medicine CrossRef
2. Were economic evaluations well reported for the newly listed oncology drugs in China’s national reimbursement drug list
   Liu Liu et al, 2022, BMC Health Services Research CrossRef
3. Clinical outcomes and safety of osimertinib plus anlotinib for patients with previously treated EGFR T790M‐positive NSCLC: A retrospective study
   Bin Zhou et al, 2022, Journal of Clinical Pharmacy and Therapeutics CrossRef
4. Sponsorship bias in published pharmacoeconomic evaluations of national reimbursement negotiation drugs in China: a systematic review
   Zixuan He et al, 2023, BMJ Global Health CrossRef
5. A state-of-the-art review of stratified medicine in cancer: towards a future precision medicine strategy in cancer
   G. Middleton et al, 2022, Annals of Oncology CrossRef
6. A systematic review of economic evaluations of tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC)
   Joo-Young Byun et al, 2022, Expert Opinion on Pharmacotherapy CrossRef